Human Microbiome Market - Global Forecast to 2031
商品番号 : SMB-14100
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 371 |
| 図表数 | 480 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、ヒトマイクロバイオーム市場を、製品別（ヒトマイクロバイオーム医薬品、ヒトマイクロバイオームサプリメント[プロバイオティクス、プレバイオティクス、シンバイオティクス]、ヒトマイクロバイオーム診断）、疾患別（感染症、胃腸疾患、内分泌・代謝疾患、がん、その他の疾患）、医薬品・サプリメントの種類別（細菌コンソーシアム移植（BCT）/糞便微生物叢移植（FMT）、ペプチド、生細菌製品、その他）、医薬品・サプリメントの投与経路別（経口、直腸）、エンドユーザー別（病院・診療所、長期ケア施設、その他のエンドユーザー）、製造サービス別（菌株開発・最適化、発酵・下流工程、製剤・充填・仕上げ、その他のサービス）および地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。本レポートは、ヒトマイクロバイオーム市場の成長に影響を与える主要な要因（推進要因、課題、機会、制約など）に関する詳細な情報を網羅しています。主要企業を詳細に分析し、事業概要、サービスポートフォリオ、主要戦略（協業、パートナーシップ、事業拡大、契約、買収など）、そしてヒトマイクロバイオーム市場に関連する最近の動向に関する洞察を提供しています。本レポートでは、ヒトマイクロバイオーム市場エコシステムにおける主要企業と新興企業の競合分析も網羅しています。
本レポートは、ヒトマイクロバイオーム市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・新サービスの発売、買収、そしてヒトマイクロバイオーム市場に関連する最近の動向に関する洞察を提供しています。本レポートは、ヒトマイクロバイオーム市場エコシステムにおける新興スタートアップ企業の競合分析を網羅しています。
本レポートは、ヒトマイクロバイオーム市場全体とそのサブセグメントの収益数値に最も近い概算値を提供することで、市場リーダー／新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。
ヒトマイクロバイオーム市場は、2024年の14億米ドルから2031年には70億9000万米ドルに達し、予測期間中に31.0%の年平均成長率（CAGR）で成長すると予測されています。マイクロバイオーム研究におけるマイクロバイオーム産業界と学術界の協力体制や、個別化医療への需要の高まりなどが、ヒトマイクロバイオーム市場の成長を牽引しています。しかしながら、複雑な規制政策がマイクロバイオームの商業化に悪影響を及ぼし、市場の成長を抑制しています。
2024年には、プロバイオティクスセグメントがヒトマイクロバイオームサプリメントセグメントで最大のシェアを占めました。
The Human Microbiome market is expected to reach USD 7.09 billion in 2031 from USD 1.40 billion in 2024, at a CAGR of 31.0% during the forecast period. Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the human microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.
The probiotics segment accounted for the largest share of the human microbiome supplements segment in 2024.
The market is segmented into human microbiome drugs, human microbiome supplements, and human microbiome diagnostics. The human microbiome supplements are analyzed across three key products: probiotics, prebiotics, and synbiotics. The segment with the biggest share in the human microbiome market in 2024 is probiotics. This dominance is attributed to their widespread use, strong consumer awareness, and established presence in over-the-counter health and wellness products. Probiotics are commonly used to support digestive health, boost immunity, and maintain gut microbial balance, making them a routine part of preventive healthcare. They are available in various formats, including capsules, powders, beverages, and functional foods, enhancing accessibility and consumer adoption. Additionally, a large body of clinical research supports the efficacy of specific probiotic strains, reinforcing trust among consumers and healthcare providers. The ability to pair probiotics with other bioactives like prebiotics or vitamins has further expanded their appeal across various demographics. Collectively, these factors have made probiotics the leading product type in the human microbiome supplements segment.
In 2024, the gastrointestinal diseases segment accounted for the largest share of the market.
The human microbiome market is segmented into gastrointestinal diseases, infectious diseases, endocrine & metabolic disorders, and other diseases. In 2024, the gastrointestinal diseases segment accounted for the largest share of the market. This is driven by the strong association between gut microbiota and conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease. These chronic disorders have a high global prevalence and often require long-term management, creating demand for alternative and adjunctive therapies that target the gut microbiome.
A growing body of research supports the role of microbial imbalances in the development and progression of gastrointestinal conditions, prompting increased investment in microbiome-based diagnostics and treatments. Several clinical-stage products targeting IBD and IBS are in development, reflecting scientific interest and unmet patient needs. The availability of microbiome supplements aimed at digestive health, such as probiotics and synbiotics, has further expanded consumer access and contributed to market growth in this segment.
In 2024, North America accounted for the largest share of the human microbiome market.
North America accounted for the largest share of the human microbiome market in 2024. This is due to several factors, including a strong presence of key market players, advanced healthcare infrastructure, and high levels of investment in microbiome research and development. The region hosts numerous clinical trials and academic collaborations focused on microbiome science, particularly in the United States. Regulatory support has also contributed to market growth, with the US FDA approving the first microbiome-based therapeutics, such as VOWST and Rebyota, setting important regulatory precedents. In addition, North America has a large and growing consumer base for microbiome supplements, particularly probiotics and synbiotics, driven by rising awareness of gut health and preventive wellness. High healthcare spending, increasing prevalence of chronic diseases, and favorable reimbursement policies further reinforce the leading position of North America in the global human microbiome market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives – 55%, Directors- 20%, and Others- 25%
- By Region: North America -45%, Europe – 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%
Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) are some of the key companies offering human microbiome drugs & supplements.
Research Coverage
This research report categorizes the Human Microbiome market by Product (Human Microbiome Drugs, Human Microbiome Supplements [Probiotics, Prebiotics, Synbiotics], Human Microbiome Diagnostics), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Drugs & Supplements Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Bacteria Products, and Others), Drugs & Supplements Route of Administration (Oral, Rectal), End User (Hospitals & Clinics, Long-term care Facilities, Other End Users), Manufacturing Service (Strain Development & Optimization, Fermentation & Downstream Processing, Formulation & Fill/Finish, Other Services) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the human microbiome market ecosystem is covered in this report.
The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the human microbiome market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the human microbiome market. This report covers the competitive analysis of upcoming startups in the human microbiome market ecosystem.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Startups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the human microbiome market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market
Competitive Assessment: Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) among others in the market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 35
1.3.2 INCLUSIONS AND EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 36
1.5 STAKEHOLDERS 37
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
2.2 MARKET SIZE ESTIMATION METHODOLOGY 41
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 43
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 44
2.3 GROWTH RATE PROJECTIONS 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.5 RESEARCH ASSUMPTIONS 47
2.6 RESEARCH LIMITATIONS 48
2.7 RISK ANALYSIS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 54
4.1 HUMAN MICROBIOME MARKET OVERVIEW 54
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024 55
4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031 55
4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
5.2.1 DRIVERS 58
5.2.1.1 Collaborative initiatives between organizations and academia 58
5.2.1.2 Increasing number of startups/SMEs exploring microbiome 60
5.2.1.3 Advancements in microbiome sequencing 62
5.2.2 RESTRAINTS 62
5.2.2.1 Complex regulatory policies 62
5.2.2.2 High investments in commercializing microbiome drugs 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Increasing demand for personalized medicines 64
5.2.3.2 Emergence of postbiotics 65
5.2.4 CHALLENGES 65
5.2.4.1 Slow patient adoption of microbiome-based therapies 65
5.2.4.2 Complexities in developing microbiome therapies 66
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66
5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY 67
5.3.1.1 Market readiness 68
5.3.1.2 Adoption 68
5.3.1.3 Maturity 68
5.4 PRICING ANALYSIS 69
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 71
5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 73
5.5 VALUE CHAIN ANALYSIS 75
5.5.1 HUMAN MICROBIOME DRUGS 75
5.5.2 HUMAN MICROBIOME SUPPLEMENTS 76
5.5.3 HUMAN MICROBIOME DIAGNOSTICS 77
5.6 ECOSYSTEM ANALYSIS 78
5.6.1 ECOSYSTEM SHIFT 79
5.6.1.1 Specialized raw material and data suppliers 79
5.6.1.2 Hot-bet innovator startups 80
5.6.1.3 Integrated end users and prosumer models 80
5.6.1.4 Regulatory and quality assurance orchestrators 80
5.6.1.5 Diagnostics-driven personalization 81
5.6.1.6 Microbiome-as-a-Service (Maas) 81
5.6.2 EMERGING BUSINESS MODELS 81
5.6.2.1 Emerging B2C model 81
5.6.2.2 Personalized supplements model 81
5.6.3 INTERCONNECTED MARKET DYNAMICS 82
5.7 INVESTMENT AND FUNDING SCENARIO 82
5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS 83
5.7.2 OTHER INVESTMENTS AND FUNDING 86
5.8 TECHNOLOGY ANALYSIS 88
5.8.1 KEY TECHNOLOGIES 88
5.8.1.1 Whole-genome sequencing 88
5.8.1.2 16s RNA sequencing method 88
5.8.1.3 Nanopore sequencing 88
5.8.2 COMPLEMENTARY TECHNOLOGIES 89
5.8.2.1 Metatranscriptomics 89
5.8.2.2 Metagenomics 89
5.8.2.3 Metabolomics 90
5.8.3 ADJACENT TECHNOLOGIES 90
5.8.3.1 Sample preparation 90
5.8.3.2 Data analysis 91
5.8.3.3 Library synthesis 91
5.9 PATENT ANALYSIS 92
5.10 KEY CONFERENCES AND EVENTS, 2025–2026 95
5.11 CASE STUDY ANALYSIS 96
5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION 96
5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION 96
5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS 97
5.12 TARIFF AND REGULATORY ANALYSIS 97
5.12.1 TARIFF DATA (HS CODE 3002.90) 97
5.12.2 REGULATORY LANDSCAPE 98
5.12.2.1 North America 98
5.12.2.1.1 US 98
5.12.2.1.2 Canada 99
5.12.2.2 Europe 99
5.12.2.2.1 UK 100
5.12.2.3 Asia Pacific 101
5.12.2.3.1 China 101
5.12.2.3.2 Japan 101
5.12.2.3.3 South Korea 102
5.12.2.3.4 Australia 102
5.12.2.3.5 Rest of Asia Pacific 103
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.13 PORTER’S FIVE FORCES ANALYSIS 107
5.13.1 BARGAINING POWER OF SUPPLIERS 108
5.13.2 BARGAINING POWER OF BUYERS 108
5.13.3 THREAT OF NEW ENTRANTS 109
5.13.4 THREAT OF SUBSTITUTES 109
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 109
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 110
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
5.14.2 BUYING CRITERIA 111
5.15 PIPELINE ANALYSIS 112
5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 114
5.16.1 INTRODUCTION 114
5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET 114
5.16.3 AI USE CASES 115
5.16.4 KEY PLAYERS IMPLEMENTING AI 115
5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET 116
5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET 117
5.17.1 KEY TARIFF RATES 117
5.17.2 PRICE IMPACT ANALYSIS 118
5.17.3 KEY IMPACT ON COUNTRY/REGION 119
5.17.3.1 US 119
5.17.3.2 Europe 119
5.17.3.3 Asia Pacific 120
5.17.3.4 Rest of the World 120
5.17.4 IMPACT ON END-USE INDUSTRY 120
5.17.4.1 Hospitals and clinics 120
5.17.4.2 Long-term care facilities 121
5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS 121
5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET 122
5.19.1 TYPE 122
5.19.2 DISEASE 122
5.19.3 END USER 123
6 HUMAN MICROBIOME MARKET, BY PRODUCT 124
6.1 INTRODUCTION 125
6.2 DRUGS 125
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET 125
6.3 SUPPLEMENTS 129
6.3.1 PROBIOTICS 132
6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth 132
6.3.2 PREBIOTICS 135
6.3.2.1 Rising development of targeted prebiotics to expedite growth 135
6.3.3 SYNBIOTICS 138
6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market 138
6.4 DIAGNOSTICS 141
6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH 141
7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE 145
7.1 INTRODUCTION 146
7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 146
7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH 146
7.3 LIVE BACTERIA PRODUCTS (LBP) 148
7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH 148
7.4 OTHER MICROBIOME TYPES 151
8 HUMAN MICROBIOME MARKET, BY DISEASE 155
8.1 INTRODUCTION 156
8.2 INFECTIOUS DISEASES 156
8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH 156
8.3 GASTROINTESTINAL DISEASES 159
8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH 159
8.4 ENDOCRINE & METABOLIC DISORDERS 162
8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET 162
8.5 OTHER DISEASES 165
9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION 169
9.1 INTRODUCTION 170
9.2 ORAL ROUTE OF ADMINISTRATION 170
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH 170
9.3 RECTAL ROUTE OF ADMINISTRATION 173
9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH 173
10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE 176
10.1 INTRODUCTION 177
10.2 STRAIN DEVELOPMENT & OPTIMIZATION 177
10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET 177
10.3 FERMENTATION & DOWNSTREAM PROCESSING 178
10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET 178
10.4 FORMULATION & FILL/FINISH 178
10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH 178
10.5 OTHER SERVICES 178
11 HUMAN MICROBIOME MARKET, BY END USER 180
11.1 INTRODUCTION 181
11.2 HOSPITALS & CLINICS 181
11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH 181
11.3 LONG-TERM CARE FACILITIES 184
11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET 184
11.4 OTHER END USERS 187
12 HUMAN MICROBIOME MARKET, BY REGION 191
12.1 INTRODUCTION 192
12.2 NORTH AMERICA 192
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 195
12.2.2 US 196
12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market 196
12.2.3 CANADA 199
12.2.3.1 Increasing prevalence of chronic diseases to expedite growth 199
12.3 EUROPE 201
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 204
12.3.2 GERMANY 205
12.3.2.1 Rapid increase in government and private funding to propel market 205
12.3.3 UK 208
12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth 208
12.3.4 FRANCE 210
12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market 210
12.3.5 ITALY 213
12.3.5.1 Rise in research activities to encourage growth 213
12.3.6 SPAIN 216
12.3.6.1 Favorable microbiome research landscape to support growth 216
12.3.7 REST OF EUROPE 219
12.4 ASIA PACIFIC 221
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 225
12.4.2 CHINA 226
12.4.2.1 Rapidly expanding healthcare industry to accelerate growth 226
12.4.3 JAPAN 229
12.4.3.1 Booming geriatric population to contribute to growth 229
12.4.4 INDIA 231
12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth 231
12.4.5 SOUTH KOREA 234
12.4.5.1 Booming bio-health market to advance growth 234
12.4.6 AUSTRALIA 237
12.4.6.1 Growing number of product approvals to boost markt 237
12.4.7 REST OF ASIA PACIFIC 239
12.5 LATIN AMERICA 242
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 244
12.5.2 BRAZIL 245
12.5.2.1 Rising probiotics demand to drive market 245
12.5.3 REST OF LATIN AMERICA 247
12.6 MIDDLE EAST 249
12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 252
12.6.2 GCC COUNTRIES 253
12.6.2.1 Saudi Arabia 255
12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market 255
12.6.2.2 UAE 258
12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth 258
12.6.2.3 Rest of GCC countries 260
12.6.3 REST OF MIDDLE EAST 263
12.7 AFRICA 265
12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME
TO PROMOTE GROWTH 265
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 267
13 COMPETITIVE LANDSCAPE 269
13.1 INTRODUCTION 269
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 269
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET 269
13.3 REVENUE ANALYSIS, 2022–2024 272
13.4 MARKET SHARE ANALYSIS, 2024 273
13.5 COMPANY VALUATION AND FINANCIAL METRICS 276
13.6 BRAND/PRODUCT COMPARISON 277
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 279
13.7.1 STARS 279
13.7.2 EMERGING LEADERS 279
13.7.3 PERVASIVE PLAYERS 279
13.7.4 PARTICIPANTS 279
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 281
13.7.5.1 Company footprint 281
13.7.5.2 Region footprint 282
13.7.5.3 Product footprint 283
13.7.5.4 Type footprint 284
13.7.5.5 Disease footprint 285
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 286
13.8.1 PROGRESSIVE COMPANIES 286
13.8.2 RESPONSIVE COMPANIES 286
13.8.3 DYNAMIC COMPANIES 286
13.8.4 STARTING BLOCKS 286
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 288
13.8.5.1 Detailed list of key startups/SMEs 288
13.8.5.2 Competitive benchmarking of key emerging players/startups 289
13.9 COMPETITIVE SCENARIO 290
13.9.1 PRODUCT LAUNCHES AND APPROVALS 290
13.9.2 DEALS 291
13.9.3 EXPANSIONS 292
14 COMPANY PROFILES 294
14.1 KEY PLAYERS 294
14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC. 294
14.1.1.1 Business overview 294
14.1.1.2 Products offered 295
14.1.1.3 Recent developments 297
14.1.1.3.1 Deals 297
14.1.1.3.2 Expansions 298
14.1.1.4 MnM view 298
14.1.1.4.1 Key strengths 298
14.1.1.4.2 Strategic choices 298
14.1.1.4.3 Weaknesses and competitive threats 299
14.1.2 SEED HEALTH, INC. 300
14.1.2.1 Business overview 300
14.1.2.2 Products offered 300
14.1.2.3 Recent developments 301
14.1.2.3.1 Product launches and approvals 301
14.1.2.3.2 Deals 302
14.1.2.3.3 Expansions 302
14.1.2.4 MnM view 303
14.1.2.4.1 Key strengths 303
14.1.2.4.2 Strategic choices 303
14.1.2.4.3 Weaknesses and competitive threats 303
14.1.3 SERES THERAPEUTICS 304
14.1.3.1 Business overview 304
14.1.3.2 Products offered 305
14.1.3.3 Recent developments 305
14.1.3.3.1 Product launches and approvals 305
14.1.3.3.2 Deals 306
14.1.3.4 MnM view 306
14.1.3.4.1 Key strengths 306
14.1.3.4.2 Strategic choices 306
14.1.3.4.3 Weaknesses and competitive threats 307
14.1.4 FERRING B.V. 308
14.1.4.1 Business overview 308
14.1.4.2 Products offered 309
14.1.4.3 Recent developments 310
14.1.4.3.1 Product launches and approvals 310
14.1.4.3.2 Deals 310
14.1.4.4 MnM view 311
14.1.4.4.1 Key strengths 311
14.1.4.4.2 Strategic choices 311
14.1.4.4.3 Weaknesses and competitive threats 311
14.1.5 PENDULUM 312
14.1.5.1 Business overview 312
14.1.5.2 Products offered 312
14.1.5.3 Recent developments 313
14.1.5.3.1 Product launches and approvals 313
14.1.5.3.2 Deals 313
14.1.5.4 MnM view 314
14.1.5.4.1 Key strengths 314
14.1.5.4.2 Strategic choices 314
14.1.5.4.3 Weaknesses and competitive threats 314
14.1.6 OPTIBIOTIX HEALTH PLC 315
14.1.6.1 Business overview 315
14.1.6.2 Products offered 316
14.1.6.3 Recent developments 317
14.1.6.3.1 Product launches and approvals 317
14.1.6.3.2 Deals 318
14.1.7 BIOGAIA 319
14.1.7.1 Business overview 319
14.1.7.2 Products offered 320
14.1.7.3 Recent developments 321
14.1.7.3.1 Product launches and approvals 321
14.1.7.3.2 Deals 321
14.1.7.3.3 Expansions 322
14.1.8 MAAT PHARMA 323
14.1.8.1 Business overview 323
14.1.8.2 Products offered 324
14.1.8.3 Recent developments 324
14.1.8.3.1 Deals 324
14.1.8.3.2 Other developments 325
14.1.9 MICROBA 326
14.1.9.1 Business overview 326
14.1.9.2 Products offered 327
14.1.9.3 Recent developments 327
14.1.9.3.1 Product launches and approvals 327
14.1.10 BIOMEBANK 328
14.1.10.1 Business overview 328
14.1.10.2 Products offered 328
14.1.10.3 Recent developments 329
14.1.10.3.1 Product launches and approvals 329
14.1.10.3.2 Deals 329
14.1.10.3.3 Expansions 329
14.1.11 BIOHM HEALTH 330
14.1.11.1 Business overview 330
14.1.11.2 Products offered 330
14.1.11.3 Recent developments 332
14.1.11.3.1 Deals 332
14.1.12 ACTIAL FARMACEUTICA SRL 334
14.1.12.1 Business overview 334
14.1.12.2 Products offered 334
14.1.13 RESBIOTIC 335
14.1.13.1 Business overview 335
14.1.13.2 Products offered 335
14.1.13.3 Recent developments 336
14.1.13.3.1 Product launches and approvals 336
14.1.13.3.2 Deals 336
14.1.13.3.3 Expansions 337
14.1.14 INFINANT HEALTH INC. 338
14.1.14.1 Business overview 338
14.1.14.2 Products offered 338
14.1.14.3 Recent developments 339
14.1.14.3.1 Deals 339
14.1.15 EXEGI PHARMA 340
14.1.15.1 Business overview 340
14.1.15.2 Products offered 340
14.1.15.3 Recent developments 341
14.1.15.3.1 Deals 341
14.1.16 FINCH THERAPEUTICS GROUP, INC. 342
14.1.16.1 Business overview 342
14.1.16.2 Products offered 343
14.1.16.3 Recent developments 343
14.1.16.3.1 Deals 343
14.1.17 INFANT BACTERIAL THERAPEUTICS AB 344
14.1.17.1 Business overview 344
14.1.17.2 Products offered 344
14.1.18 VIOME LIFESCIENCES 346
14.1.18.1 Business overview 346
14.1.18.2 Products offered 346
14.1.18.3 Recent developments 347
14.1.18.3.1 Product launches and approvals 347
14.1.19 GENOVA DIAGNOSTICS 348
14.1.19.1 Business overview 348
14.1.19.2 Products offered 348
14.2 OTHER PLAYERS 349
14.2.1 AOBIOME 349
14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD. 350
14.2.3 NUBIYOTA 351
14.2.4 OXTHERA 352
14.2.5 NEXBIOME 353
14.2.6 VEDANTA BIOSCIENCES, INC. 354
14.2.7 ENTEROME 355
14.2.8 APSEN FARMACÊUTICA 356
14.2.9 METAGEN, INC. 357
14.2.10 SNIPR BIOME 358
14.2.11 MIKROBIOMIK 359
14.2.12 SYNLOGIC 360
14.2.13 GENETIC ANALYSIS 361
14.2.14 METABIOMICS 361
14.2.15 SUN GENOMICS, INC. 362
15 APPENDIX 363
15.1 DISCUSSION GUIDE 363
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367
15.3 CUSTOMIZATION OPTIONS 369
15.4 RELATED REPORTS 369
15.5 AUTHOR DETAILS 370
LIST OF TABLES
TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 46
TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS 48
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 58
TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022–2024 59
TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET 61
TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 (USD) 71
TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022–2024 (USD) 73
TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022–2024 83
TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024 93
TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 95
TABLE 12 TARIFF DATA FOR HS CODE 3002.90 98
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 103
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS 106
TABLE 18 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 107
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 110
TABLE 20 KEY BUYING CRITERIA, BY END USER 111
TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME 115
TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET 116
TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES 117
TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN 118
TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 119
TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT 121
TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 125
TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE 126
TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023–2031 (USD MILLION) 128
TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 128
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 129
TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 129
TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION,
2023–2031 (USD MILLION) 130
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 130
TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 130
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 131
TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 131
TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION,
2023–2031 (USD MILLION) 131
TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 132
TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION) 133
TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 133
TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 133
TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 134
TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 134
TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023–2031 (USD MILLION) 134
TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 135
TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023–2031 (USD MILLION) 136
TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 136
TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 136
TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 137
TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 137
TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS,
BY REGION, 2023–2031 (USD MILLION) 137
TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 138
TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023–2031 (USD MILLION) 139
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 139
TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 139
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS,
BY COUNTRY, 2023–2031 (USD MILLION) 140
TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 140
TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS,
BY REGION, 2023–2031 (USD MILLION) 140
TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023–2031 (USD MILLION) 141
TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION,
2023–2031 (USD MILLION) 142
TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 142
TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 142
TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 143
TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION,
2023–2031 (USD MILLION) 143
TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 144
TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 146
TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023–2031 (USD MILLION) 147
TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION) 147
TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023–2031 (USD MILLION) 148
TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION) 149
TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 149
TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 149
TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 150
TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 150
TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023–2031 (USD MILLION) 150
TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023–2031 (USD MILLION) 151
TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION) 152
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 152
TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 152
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET
FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 153
TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET
FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 153
TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023–2031 (USD MILLION) 153
TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023–2031 (USD MILLION) 154
TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 156
TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS
FOR INFECTIOUS DISEASES 157
TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2023–2031 (USD MILLION) 158
TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 158
TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 159
TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 160
TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 160
TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 161
TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161
TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 161
TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION) 162
TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 162
TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS,
BY REGION, 2023–2031 (USD MILLION) 163
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE &
METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 163
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164
TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 164
TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2031 (USD MILLION) 165
TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 165
TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION,
2023–2031 (USD MILLION) 166
TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 166
TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 167
TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 167
TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 167
TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2031 (USD MILLION) 168
TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 168
TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 170
TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 171
TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 171
TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 171
TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 172
TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 172
TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 172
TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 173
TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL
ROUTE OF ADMINISTRATION, BY REGION, 2023–2031 (USD MILLION) 174
TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 174
TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2031 (USD MILLION) 175
TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE,
2023–2031 (USD MILLION) 177
TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 181
TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION,
2023–2031 (USD MILLION) 182
TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2031 (USD MILLION) 182
TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2031 (USD MILLION) 182
TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2031 (USD MILLION) 183
TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2031 (USD MILLION) 183
TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2023–2031 (USD MILLION) 183
TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2023–2031 (USD MILLION) 184
TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION) 185
TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 185
TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2023–2031 (USD MILLION) 185
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 186
TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 186
TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2031 (USD MILLION) 186
TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2031 (USD MILLION) 187
TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION,
2023–2031 (USD MILLION) 188
TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 188
TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 188
TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 189
TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 189
TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY REGION, 2023–2031 (USD MILLION) 189
TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2031 (USD MILLION) 190
TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023–2031 (USD MILLION) 192
TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 193
TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 194
TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 194
TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 194
TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 195
TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 195
TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 195
TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 196
TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 197
TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 197
TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 198
TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 198
TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 198
TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 199
TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 199
TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 200
TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 200
TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 200
TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 201
TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 201
TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 202
TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 202
TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 202
TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 203
TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 203
TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 203
TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 204
TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS 205
TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 206
TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 206
TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 206
TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 207
TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 207
TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 207
TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 208
TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 209
TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 209
TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 209
TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 210
TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 210
TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE 211
TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 211
TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 212
TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 212
TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 212
TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 213
TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 213
TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 214
TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 214
TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 215
TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 215
TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 215
TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 216
TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 217
TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 217
TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 217
TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 218
TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 218
TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 218
TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 219
TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 219
TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 220
TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 220
TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 220
TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 221
TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 223
TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 223
TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 223
TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 224
TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 224
TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 224
TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 225
TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS 225
TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 227
TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 227
TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 227
TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 228
TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 228
TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 228
TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 229
TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 230
TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 230
TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 230
TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 231
TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 231
TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA 232
TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 232
TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 232
TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 233
TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 233
TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 233
TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 234
TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 235
TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 235
TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 235
TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 236
TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 236
TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 236
TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 237
TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 238
TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 238
TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 238
TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 239
TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 239
TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 240
TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 240
TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 240
TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 241
TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 241
TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 241
TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 242
TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 242
TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 242
TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 243
TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 243
TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 243
TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 244
TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 244
TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 245
TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 245
TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 246
TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 246
TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 246
TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 247
TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 247
TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 248
TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 248
TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 248
TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 249
TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 249
TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION,
2023–2031 (USD MILLION) 250
TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 250
TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 250
TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 251
TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 251
TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 251
TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 252
TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 252
TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 253
TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 253
TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 253
TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 254
TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 254
TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 254
TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 255
TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 256
TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 256
TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 256
TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 257
TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 257
TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 257
TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 258
TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 259
TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 259
TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 259
TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 260
TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023–2031 (USD MILLION) 260
TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 261
TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET,
BY TYPE, 2023–2031 (USD MILLION) 261
TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 261
TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 262
TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 262
TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 262
TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2031 (USD MILLION) 263
TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 264
TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 264
TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 264
TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE,
2023–2031 (USD MILLION) 265
TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 265
TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2031 (USD MILLION) 266
TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 266
TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE,
2023–2031 (USD MILLION) 266
TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2031 (USD MILLION) 267
TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2031 (USD MILLION) 267
TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER,
2023–2031 (USD MILLION) 267
TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS 268
TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022–JULY 2025 269
TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024 274
TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT 282
TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT 283
TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT 284
TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT 285
TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES 288
TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF
KEY EMERGING PLAYERS/STARTUPS 289
TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND
APPROVALS, JANUARY 2022–JULY 2025 290
TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022–JULY 2025 291
TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022–JULY 2025 292
TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW 294
TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED 295
TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS,
JANUARY 2022–JULY 2025 297
TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS,
JANUARY 2022–JULY 2025 298
TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW 300
TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED 300
TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 301
TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022–JULY 2025 302
TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022−JULY 2025 302
TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW 304
TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED 305
TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 305
TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022–JULY 2025 306
TABLE 347 FERRING B.V.: COMPANY OVERVIEW 308
TABLE 348 FERRING B.V.: PRODUCTS OFFERED 309
TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 310
TABLE 350 FERRING B.V.: DEALS, JANUARY 2022–JULY 2025 310
TABLE 351 PENDULUM: COMPANY OVERVIEW 312
TABLE 352 PENDULUM: PRODUCTS OFFERED 312
TABLE 353 PENDULUM: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 313
TABLE 354 PENDULUM: DEALS, JANUARY 2022–JULY 2025 313
TABLE 355 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW 315
TABLE 356 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED 316
TABLE 357 OPTIBIOTIX HEALTH PLC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 317
TABLE 358 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2022–JULY 2025 318
TABLE 359 BIOGAIA: COMPANY OVERVIEW 319
TABLE 360 BIOGAIA: PRODUCTS OFFERED 320
TABLE 361 BIOGAIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 321
TABLE 362 BIOGAIA: DEALS, JANUARY 2022–JULY 2025 321
TABLE 363 BIOGAIA: EXPANSIONS, JANUARY 2022–JULY 2025 322
TABLE 364 MAAT PHARMA: COMPANY OVERVIEW 323
TABLE 365 MAAT PHARMA: PRODUCTS OFFERED 324
TABLE 366 MAAT PHARMA: DEALS, JANUARY 2022–JULY 2025 324
TABLE 367 MAAT PHARMA: OTHER DEVELOPMENTS, JANUARY 2022−JULY 2025 325
TABLE 368 MICROBA: COMPANY OVERVIEW 326
TABLE 369 MICROBA: PRODUCTS OFFERED 327
TABLE 370 MICROBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 327
TABLE 371 BIOMEBANK: COMPANY OVERVIEW 328
TABLE 372 BIOMEBANK: PRODUCTS OFFERED 328
TABLE 373 BIOMEBANK: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 329
TABLE 374 BIOMEBANK: DEALS, JANUARY 2022–JULY 2025 329
TABLE 375 BIOMEBANK: EXPANSIONS, JANUARY 2022–JULY 2025 329
TABLE 376 BIOHM HEALTH: COMPANY OVERVIEW 330
TABLE 377 BIOHM HEALTH: PRODUCTS OFFERED 330
TABLE 378 BIOHM HEALTH: DEALS, JANUARY 2022–JULY 2025 332
TABLE 379 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW 334
TABLE 380 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED 334
TABLE 381 RESBIOTIC: COMPANY OVERVIEW 335
TABLE 382 RESBIOTIC: PRODUCTS OFFERED 335
TABLE 383 RESBIOTIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 336
TABLE 384 RESBIOTIC: DEALS, JANUARY 2022–JULY 2025 336
TABLE 385 RESBIOTIC: EXPANSIONS, JANUARY 2022–JULY 2025 337
TABLE 386 INFINANT HEALTH INC.: COMPANY OVERVIEW 338
TABLE 387 INFINANT HEALTH INC.: PRODUCTS OFFERED 338
TABLE 388 INFINANT HEALTH INC.: DEALS, JANUARY 2022–JULY 2025 339
TABLE 389 EXEGI PHARMA: COMPANY OVERVIEW 340
TABLE 390 EXEGI PHARMA: PRODUCTS OFFERED 340
TABLE 391 EXEGI PHARMA: DEALS, JANUARY 2022–JULY 2025 341
TABLE 392 FINCH THERAPEUTICS GROUP, INC.: COMPANY OVERVIEW 342
TABLE 393 FINCH THERAPEUTICS GROUP, INC.: PRODUCTS OFFERED 343
TABLE 394 FINCH THERAPEUTICS GROUP, INC.: DEALS, JANUARY 2022–JULY 2025 343
TABLE 395 INFANT BACTERIAL THERAPEUTICS AB: COMPANY OVERVIEW 344
TABLE 396 INFANT BACTERIAL THERAPEUTICS AB: PRODUCTS OFFERED 344
TABLE 397 VIOME LIFESCIENCES: COMPANY OVERVIEW 346
TABLE 398 VIOME LIFESCIENCES: PRODUCTS OFFERED 346
TABLE 399 VIOME LIFESCIENCES: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–JULY 2025 347
TABLE 400 GENOVA DIAGNOSTICS: COMPANY OVERVIEW 348
TABLE 401 GENOVA DIAGNOSTICS: PRODUCTS OFFERED 348
TABLE 402 AOBIOME: COMPANY OVERVIEW 349
TABLE 403 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 350
TABLE 404 NUBIYOTA: COMPANY OVERVIEW 351
TABLE 405 OXTHERA: COMPANY OVERVIEW 352
TABLE 406 NEXBIOME: COMPANY OVERVIEW 353
TABLE 407 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW 354
TABLE 408 ENTEROME: COMPANY OVERVIEW 355
TABLE 409 APSEN FARMACÊUTICA: COMPANY OVERVIEW 356
TABLE 410 METAGEN, INC.: COMPANY OVERVIEW 357
TABLE 411 SNIPR BIOME: COMPANY OVERVIEW 358
TABLE 412 MIKROBIOMIK: COMPANY OVERVIEW 359
TABLE 413 SYNLOGIC: COMPANY OVERVIEW 360
TABLE 414 GENETIC ANALYSIS: COMPANY OVERVIEW 361
TABLE 415 METABIOMICS: COMPANY OVERVIEW 361
TABLE 416 SUN GENOMICS, INC.: COMPANY OVERVIEW 362
LIST OF FIGURES
FIGURE 1 HUMAN MICROBIOME MARKET SEGMENTATION AND REGIONAL SCOPE 35
FIGURE 2 RESEARCH DESIGN 38
FIGURE 3 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 40
FIGURE 4 HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 41
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2024 42
FIGURE 6 ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES INC.: REVENUE SHARE ANALYSIS, 2024 42
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 43
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44
FIGURE 9 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
FIGURE 11 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION) 49
FIGURE 12 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE,
2025 VS. 2031 (USD MILLION) 50
FIGURE 13 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET,
BY TYPE, 2024 VS. 2030 (USD MILLION) 50
FIGURE 14 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2031 (USD MILLION) 51
FIGURE 15 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2031 (USD MILLION) 51
FIGURE 16 HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 52
FIGURE 17 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 52
FIGURE 18 RISING DEMAND FOR PERSONALIZED MEDICINE AND ADVANCEMENTS IN MICROBIOME SEQUENCING TO DRIVE MARKET 54
FIGURE 19 US AND LIVE BACTERIA PRODUCTS (LBP) SEGMENT LED NORTH AMERICAN MARKET IN 2024 55
FIGURE 20 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55
FIGURE 21 US TO DOMINATE GLOBAL MARKET DURING FORECAST PERIOD 56
FIGURE 22 HOSPITALS & CLINICS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2025 56
FIGURE 23 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 57
FIGURE 24 COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS 63
FIGURE 25 HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66
FIGURE 26 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY 67
FIGURE 28 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY
PLAYER, 2024 (USD) 70
FIGURE 29 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DIAGNOSTICS, BY KEY PLAYER, 2024 (USD) 70
FIGURE 30 AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME SUPPLEMENTS & DIAGNOSTICS, BY TYPE, 2022–2024 (USD) 73
FIGURE 31 AVERAGE SELLING PRICE OF HUMAN MICROBIOME SUPPLEMENTS,
BY REGION, 2024 (USD) 74
FIGURE 32 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DRUGS 75
FIGURE 33 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME SUPPLEMENTS 76
FIGURE 34 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DIAGNOSTICS 77
FIGURE 35 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 79
FIGURE 36 HUMAN MICROBIOME MARKET: INVESTMENT AND FUNDING SCENARIO,
2022–2024 82
FIGURE 37 HUMAN MICROBIOME MARKET: PATENT ANALYSIS,
JANUARY 2014–DECEMBER 2024 92
FIGURE 38 REGULATORY LANDSCAPE OF LIVE BACTERIA PRODUCTS (LBP) 107
FIGURE 39 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 108
FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 110
FIGURE 41 KEY BUYING CRITERIA, BY END USER 111
FIGURE 42 HUMAN MICROBIOME PIPELINE, BY DISEASE 112
FIGURE 43 HUMAN MICROBIOME PIPELINE, BY PHASE 113
FIGURE 44 HUMAN MICROBIOME PIPELINE, BY REGION 113
FIGURE 45 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET 114
FIGURE 46 AI USE CASES 115
FIGURE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 193
FIGURE 48 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 222
FIGURE 49 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET,
2022–2024 (USD MILLION) 272
FIGURE 50 MARKET SHARE ANALYSIS OF KEY PLAYERS IN
HUMAN MICROBIOME MARKET, 2024 273
FIGURE 51 EV/EBITDA OF KEY PLAYERS 276
FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY PLAYERS 276
FIGURE 53 HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARISON 277
FIGURE 54 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 280
FIGURE 55 HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT 281
FIGURE 56 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 287
FIGURE 57 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2024) 295
FIGURE 58 SERES THERAPEUTICS: COMPANY SNAPSHOT (2023) 304
FIGURE 59 FERRING B.V.: COMPANY SNAPSHOT (2024) 309
FIGURE 60 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2024) 316
FIGURE 61 BIOGAIA: COMPANY SNAPSHOT (2024) 320
FIGURE 62 MAAT PHARMA: COMPANY SNAPSHOT (2024) 323
FIGURE 63 MICROBA: COMPANY SNAPSHOT (2024) 326
FIGURE 64 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2023) 342
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11